title: Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.
abstract: Dendritic cell (DC)-based vaccines continue to be considered an attractive tool for cancer immunotherapy. DCs require an additional signal from the environment or other immune cells to polarize the development of immune responses toward T helper 1 (Th1) or Th2 responses. DCs play a role in natural killer (NK) cell activation, and NK cells are also able to activate and induce the maturation of DCs. We investigated the types of NK cells that can induce the maturation and enhanced function of DCs and the conditions under which these interactions occur. DCs that were activated by resting NK cells in the presence of inflammatory cytokines exhibited increased expression of several costimulatory molecules and an enhanced ability to produce IL-12p70. NK cell-stimulated DCs potently induced Th1 polarization and exhibited the ability to generate tumor antigen-specific cytotoxic T lymphocyte responses. Our data demonstrate that functional DCs can be generated by coculturing immature DCs with freshly isolated resting NK cells in the presence of Toll-like receptor agonists and proinflammatory cytokines and that the resulting DCs effectively present antigens to induce tumor-specific T-cell responses, which suggests that these cells may be useful for cancer immunotherapy.
authors.affiliation: Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea.
authors.forename: Thanh-Nhan
authors.initials: TN
authors.lastname: Nguyen-Pham
authors.forename: Deok-Hwan
authors.initials: DH
authors.lastname: Yang
authors.forename: Truc-Anh Thi
authors.initials: TA
authors.lastname: Nguyen
authors.forename: Mi-Seon
authors.initials: MS
authors.lastname: Lim
authors.forename: Cheol Yi
authors.initials: CY
authors.lastname: Hong
authors.forename: Mi-Hyun
authors.initials: MH
authors.lastname: Kim
authors.forename: Hyun Ju
authors.initials: HJ
authors.lastname: Lee
authors.forename: Youn-Kyung
authors.initials: YK
authors.lastname: Lee
authors.forename: Duck
authors.initials: D
authors.lastname: Cho
authors.forename: Soo-Young
authors.initials: SY
authors.lastname: Bae
authors.forename: Jae-Sook
authors.initials: JS
authors.lastname: Ahn
authors.forename: Yeo-Kyeoung
authors.initials: YK
authors.lastname: Kim
authors.forename: Ik-Joo
authors.initials: IJ
authors.lastname: Chung
authors.forename: Hyeoung-Joon
authors.initials: HJ
authors.lastname: Kim
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee
mesh_terms: D017951:Antigen Presentation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002478:Cells, Cultured; D018920:Coculture Techniques / Q000379:methods*; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology / Q000637:transplantation*; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D018664:Interleukin-12 / Q000276:immunology; D007694:Killer Cells, Natural / Q000166:cytology* / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D018417:Th1 Cells / Q000166:cytology / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018664:Interleukin-12